Literature DB >> 19805574

ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis.

Kevin M O'Hayer1, Donita C Brady, Christopher M Counter.   

Abstract

The small GTPase Ras is mutated to remain in the active oncogenic state in one-third of human cancers, thereby promoting tumorigenesis. It has recently come to light that one consequence of oncogenic Ras signaling is secretion of cytokines vascular endothelial growth factor (VEGF), interleukin 6 (IL6), hCXCL1 (Gro-alpha) and hCXCL8 (IL8). As the latter two belong to the ELR+ Cys-X-Cys (CXC) chemokine family, we investigated whether the entire family of ELR+ CXC chemokines plays a role in oncogenic Ras-mediated tumorigenesis. We now demonstrate that oncogenic Ras induced the expression and secretion of the ELR+ CXC chemokine family in different tumorigenic human cells and that these chemokines are elevated in tumor specimens. Moreover, genetic ablation of the common receptor for these chemokines, mCXCR2, reduced oncogenic Ras-driven tumorigenesis in mice. Taken together, we suggest that oncogenic Ras induces the secretion of the ELR+ CXC chemokine family to promote tumorigenesis. This chemokine signature may identify the presence of Ras activation in cancer and perhaps even serve as targets for oncogenic Ras-driven tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805574      PMCID: PMC2783001          DOI: 10.1093/carcin/bgp198

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  40 in total

Review 1.  The biology of chemokines and their receptors.

Authors:  D Rossi; A Zlotnik
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

Authors:  Aihua Li; Seema Dubey; Michelle L Varney; Bhavana J Dave; Rakesh K Singh
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

3.  Elevation of cytokine levels in cachectic patients with prostate carcinoma.

Authors:  Jesco Pfitzenmaier; Robert Vessella; Celestia S Higano; Jennifer L Noteboom; David Wallace; Eva Corey
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

Review 4.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

Authors:  V Janssens; J Goris
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

5.  Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer.

Authors:  S J Wigmore; K C H Fearon; K Sangster; J P Maingay; O J Garden; J A Ross
Journal:  Int J Oncol       Date:  2002-10       Impact factor: 5.650

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 7.  Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.

Authors:  Brooke B Ancrile; Kevin M O'Hayer; Christopher M Counter
Journal:  Mol Interv       Date:  2008-02

Review 8.  Distinct requirements for Ras oncogenesis in human versus mouse cells.

Authors:  Nesrin M Hamad; Joel H Elconin; Antoine E Karnoub; Wenli Bai; Jeremy N Rich; Robert T Abraham; Channing J Der; Christopher M Counter
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

9.  Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

Authors:  Brooke Ancrile; Kian-Huat Lim; Christopher M Counter
Journal:  Genes Dev       Date:  2007-07-15       Impact factor: 11.361

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  22 in total

Review 1.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

Review 2.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

3.  KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.

Authors:  Szabolcs Fatrai; Djoke van Gosliga; Lina Han; Simon M G J Daenen; Edo Vellenga; Jan Jacob Schuringa
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

4.  Identifying mutation specific cancer pathways using a structurally resolved protein interaction network.

Authors:  H Billur Engin; Matan Hofree; Hannah Carter
Journal:  Pac Symp Biocomput       Date:  2015

5.  Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.

Authors:  Ze-Yi Zheng; Lin Tian; Wen Bu; Cheng Fan; Xia Gao; Hai Wang; Yi-Hua Liao; Yi Li; Michael T Lewis; Dean Edwards; Thomas P Zwaka; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Chad J Creighton; Xiang H-F Zhang; Eric C Chang
Journal:  Cell Rep       Date:  2015-07-09       Impact factor: 9.423

6.  Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice.

Authors:  Jianjun Shen; Erika L Abel; Penny K Riggs; John Repass; Sean C Hensley; Lisa J Schroeder; Angelina Temple; Alexander Chau; S Alex McClellan; Okkyung Rho; Kaoru Kiguchi; Michael D Ward; O John Semmes; Maria D Person; Joe M Angel; John Digiovanni
Journal:  Carcinogenesis       Date:  2012-07-10       Impact factor: 4.944

7.  Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Sugandha Saxena; Caitlin Molczyk; Abhilasha Purohit; Evie Ehrhorn; Paran Goel; Dipakkumar R Prajapati; Pranita Atri; Sukhwinder Kaur; Paul M Grandgenett; Michael A Hollingsworth; Surinder K Batra; Rakesh K Singh
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

8.  Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.

Authors:  Sajjad Khan; Silke Cameron; Martina Blaschke; Federico Moriconi; Naila Naz; Ahmad Amanzada; Giuliano Ramadori; Ihtzaz Ahmed Malik
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

9.  CXCL3 Signaling in the Tumor Microenvironment.

Authors:  Niradiz Reyes; Stephanie Figueroa; Raj Tiwari; Jan Geliebter
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.

Authors:  Thomas Jamieson; Mairi Clarke; Colin W Steele; Michael S Samuel; Jens Neumann; Andreas Jung; David Huels; Michael F Olson; Sudipto Das; Robert J B Nibbs; Owen J Sansom
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.